Advanced Oncotherapy - Update on Financing Discussions
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy", "AVO" or the "Company")
Update on Financing Discussions
Further to the Company's announcement on
The Company continues to work on its recapitalisation plan with the third-party investor (the "Investor") that it entered into a non-binding term sheet with. The Company and the Investor signed an updated non-binding term sheet on
As part of the envisaged transaction (the "Financing Transaction"), inter alia, it is also expected that the Company would be required to restructure its financial liabilities with a view to providing a long-term financing solution for the Company to continue as a going concern. The Financing Transaction would also be subject to, amongst other things, approval by shareholders of the Company and consent from certain other stakeholders of the Company.
As of
The Company is also currently in advanced discussions with a third-party investor regarding a short-term loan facility which, if put in place, would provide the Company with additional short term bridge financing while the Company progresses on the Financing Transaction.
The Company has also been assessing alternatives ways to improve the balance sheet of its Swiss operating subsidiary, ADAM SA ("ADAM"). ADAM has been granted certain protections against its creditors through to
Whilst the board of the Company is hopeful of a satisfactory outcome, there can be no certainty that the Financing Transaction will proceed nor that the short-term loan facility will be put in place. Without access to the additional capital which is proposed to be provided by the Investor pursuant to the Financing Transaction, the Company is unlikely to be able to continue to trade and would very likely become insolvent and be placed into administration.
The Company's shares remain suspended from trading on AIM pending: (i) completion of the Financing Transaction; (ii) publication of the Company's annual report and accounts for the year ended
Further announcements will be made at the appropriate time.
|
Advanced Oncotherapy Plc |
|
|
Dr. |
Tel: +44 (0) 20 3617 8728 |
|
|
|
|
|
|
|
WH Ireland Limited (Financial adviser) |
Tel: +44 (0) 20 7220 1666 |
|
|
|
|
|
|
|
Allenby Capital Limited (Nomad and Joint Broker) |
|
|
|
Tel: +44 (0) 20 3328 5656 |
|
|
|
|
SI Capital Ltd (Joint Broker) |
|
|
|
Tel: +44 (0) 1483 413 500 |
|
|
Tel: +44 (0) 20 3871 4066 |
|
|
|
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy Plc, a
Advanced Oncotherapy Plc will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy Plc continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE